Overview

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.
Phase:
Phase 2
Details
Lead Sponsor:
Abbott